As Blincyto is not locally approved, it is accessed via the Named Patient Program (NPP), making cost dependent on patient-specific factors such as dosage cycles and treatment phase. The medicine is approved for treating B-cell precursor acute lymphoblastic leukemia (ALL).
Understanding the total cost requires expert guidance to ensure both compliance and affordability. Indian Pharma Network supports patients with end-to-end assistance.
Reach out to us via WhatsApp +91 98104 69557 or toll-free 1800 1200 365.
https://www.indianpharmanet ...
